The EphMRA Code of Conduct (the European Pharmaceutical Market Research Association) provides comprehensive and up-to-date key ethical and legal indications to support companies conducting research in the pharmaceutical field in different countries. This includes ad hoc and third-party research on pharmaceuticals, biologics, medical devices and diagnostic tools (available with or without prescription).
The Code is an international guideline that has been developed focusing on Brazil, Canada, Denmark, Finland, France, Germany, Greece, Italy, Japan, Korea, Mexico, the Netherlands, Norway, Poland, Russia, Turkey, Spain, Sweden , UK and USA. When necessary, the differences that distinguish one country from another, where they exist, are clearly highlighted.
Assirm, thanks to the work of the Commission for Integration Projects of the International Pharma Guideline, within the Quality Standards Committee, has translated into Italian the latest version of the EphMRA Code of Conduct (the European Pharmaceutical Market Research Association) issued in October 2017 .
At this link - http://www.ephmra.org/Code-of-Conduct-Support - you can find the original version of the document in English.
For any questions or questions about the translation you can write to email@example.com
PRINCIPLES OF THE CODE
There are twelve guiding principles that underpin the Code of Conduct:
I. Market research subjects must be able to provide voluntary, informed consent to data collection and use, based upon a clear understanding of the purpose of the data collection and the use(s) to which the data will be put.
II. The rights of Market Research subjects must be observed, including rights to confidentiality, anonymity and the right to withdraw at any stage.
III. Market research must be kept separate from any form of promotion or selling, it must not be a vehicle for disguised promotion.
IV. The subjects of market research must be treated fairly and reasonably, with care and courtesy.
V. The subjects of market research must be protected for the duration of the study – not harmed, exposed, disadvantaged or made to feel uncomfortable in any way. Confidence in market research must not be abused.
VI. Data collection must be adequate, relevant and not excessive. Researchers must be transparent about the personal data they intend to collect, the reasons why they are collected and with whom they will be shared.
VII. Data must be processed fairly and lawfully, and only used for the specific and lawful purposes for which it was obtained. Personal data must be accurate and up to date. It must be processed in accordance with the rights of individuals within national data protection and privacy legislation.
VIII. There must be no unauthorised or unlawful processing, loss, destruction or damage to personal data.
IX. Data may only be transferred to third parties or abroad when they have been adequately protected.
X. Personal data must not be kept beyond the time required to fulfil the immediate purposes of the study.
XI. Researchers must act ethically and must not undermine or harm the reputation of healthcare market research. They must not disparage or appear to disparage competing companies or products.
XII. Researchers must conduct market research in an accurate, transparent, objective and qualitatively appropriate manner.